You just read:

Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma at the American Society of Hematology 2017

News provided by

Kyowa Hakko Kirin Co., Ltd.

Dec 11, 2017, 13:31 EST